COMMUNIQUÉS West-GlobeNewswire
-
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
18/06/2026 -
Court victory paves the way for Curium’s plans to provide targeted radioligand therapy to U.S. patients with GEP-NETs
18/06/2026 -
BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth
18/06/2026 -
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
18/06/2026 -
23andMe Research Institute Appoints Hillary Aiken as Head of Philanthropy & Development
18/06/2026 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
18/06/2026 -
COUR Pharma Announces Closing of $50 Million Series B
18/06/2026 -
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
18/06/2026 -
R1 Accelerates Real-Time Adjudication with New Phare OS Intelligence Engine
18/06/2026 -
Hi*Ball Energy Arrives in the UK, Leading a New Wave of Clean Energy
18/06/2026 -
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
18/06/2026 -
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
18/06/2026 -
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
18/06/2026 -
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
18/06/2026 -
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
18/06/2026 -
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
18/06/2026 -
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
18/06/2026 -
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
18/06/2026 -
Memo Therapeutics AG Presents Complete Phase II Clinical Trial Data for Potravitug in Kidney Transplant Recipients at the American Transplant Congress 2026
18/06/2026
Pages